40, Dalton St

Boston,

MA,

USA,

ZIP: 02115

Phone: +16174554188

From Leveraging Emerging Predictive Technologies to Engineering a Human-Physiologically Relevant Models - Deepen Our Understanding of Tumor Biology, Resistance Mechanisms and Dosing Strategy

Following the success of KRAS, HER2, BCMA, drug developers have seen a new wave of the novel, combination targeted oncology surging through pipeline. The industry has reached an inflection point on establishing the benefits that a 'community of drugs' can offer to realize improved preclinical efficacy in the clinic. Translatability remains a key bottleneck with existing models' limitations - from tumor biology to dose-scheduling, from biomarker identification to safety - these are top priorities for the preclinical and translational scientists to overcome in 2022.

The 10th Tumor Models For Combination Targeted Oncology summit will finally return to the city in July. In July, the summit will unite 130+ Principal Preclinical and Translational Scientists to share their challenges and ideas for new strategies to perform their studies, equipping you with the right tools to maximize your clinical confidence and ensure patient safety.

Be part of this growing community this July to support your pipeline acceleration, and develop novel, safe and efficacious treatments for patients in need! As drug developers or academics, secure your free pass before they book up!

URLs:
Tickets: https://go.evvnt.com/1067549-2?pid=1052
Brochure: https://go.evvnt.com/1067549-3?pid=1052

Kimberly Aardalen Scientific Technical Leader Novartis Institutes for Biomedical Research, Carmine Fedele Lab Head, Principal Scientist, Pharmacology, Oncology / Drug Discovery Novartis, Thomas Schürpf Senior Director, Tumor Biology Parthenon Therapeutics, Khalid Shah Vice Chairman at BWH Harvard Medical School, Agnieszka Denslow Associate Director Pharmacology / Toxicology, Oncorus, Beatrice Wang Associate Director IGM Biosciences, Rhys Jones Senior Director Pfizer, Frank Sun Senior Principal Scientist, Oncology Pharmacology Sanofi, Jennifer O’Neil VP, Translational Oncology Xilio Therapeutics, Jessica Haverkamp Associate Director Macrophage Biology BlueRock Therapeutics, Jingjing Jiang Senior Director, Translational Research Revolution Medicines, Natalia Blanco Associate Director, Immuno-Oncology Morphic Therapeutics, Katie Grausam Postdoctoral Scientist Cedars Sinai, Ludovic Bigot Project Manager Gustav Rousey, Marc Pelletier Senior Principal Scientist Novartis, Marc Zuckermann Group Leader Preclinical Modeling German Cancer Research Center (DKFZ), Johanna Lahdenranta Director In Vivo Pharmacology Bicycle Therapeutics, Juan Arriaga Assistant Professor – Department of Oncological Sciences and Urology Icahn School of Medicine at Mount Sinai, Scott Boiko Associate Director Translational Science Forma Therapeutics, Anita Seshire Head Of Laboratory in Exploratory Cancer Research, Translational Innovation Platform Oncology- Immunooncology Merck Healthcare KGaA, Shannon Ruppert Senior Scientist Genentech, Tomasz Owczarek Senior Staff Scientist Regeneron, Soner Altiok CSO Nilogen Oncosystems, Jon Waterman-Smith Vice President Of Marketing and Business Development Nilogen Oncosystems, Jun Zhang MD, PhD, Associate Professor University of Kansas Medical Center, Medical Oncology, Javier Pineda Bioinformatics Lead Scientist.com, Marco Campisi Postdoctoral Research Fellow Dana-Farber Cancer Institute, Gareth Griffiths CSO Imagen Therapeutics, Shiva Kazerounian Associate Director of in Vivo Pharmacology Berg Health, Eric Ibsen Chief Executive Officer Studylog